Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib (NCT06648473) | Clinical Trial Compass
WithdrawnNot Applicable
Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib
Stopped: sponsor withdrew funding
United States0Started 2026-01-01
Plain-language summary
The purpose of this study is to evaluate the repeatability of magnetic resonance imaging (MRI) in patients with isocitrate dehydrogenase 1 (IDH1) mutant (mIDH1) low-grade diffuse glioma \[World Health Organization (WHO) grade 2\] who are receiving off-label ivosidenib.
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Written informed consent prior to beginning specific protocol procedures
. Scheduled for contrast-enhanced magnetic resonance imaging (MRI) as part of clinical care
. Active patient treatment or evaluations at the Preston Robert Tisch Brain Tumor Center at Duke
. Age ≥18 years and ≤70 years
. Karnofsky performance index ≥70%
. Primary treating physician approval
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1I found a trial called NCT06648473 that was studying MRI repeatability in IDH1 mutant glioma patients taking ivosidenib, but it shows as 'withdrawn' — do you know why it was withdrawn, and does that tell us anything important about ivosidenib or this imaging approach?
2Since this trial was focused on measuring how consistently MRI scans produce the same results rather than testing a new treatment directly, what would that kind of research have meant for how my disease is monitored, and are there other studies doing similar work I could ask about?
3This trial was specifically for IDH1 mutant low-grade glioma — has my tumor been tested for that IDH1 mutation, and how does knowing that status affect which trials or treatments might be worth exploring?
4Since this particular study is no longer enrolling, are there any active trials involving ivosidenib or IDH1-targeted treatments for low-grade glioma that you think would be worth looking into for my situation?
5Given that this was listed as 'Phase NA,' meaning it wasn't a standard treatment trial, how does that differ from trials that are actually testing whether a drug works, and what should I prioritize when comparing my options?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.